Effect of InnoSlim® on Blood Sugar and Blood Lipids Regulation in Humans

N/AUnknownNCT04201314

Chung Shan Medical University12 enrolled

Overview

InnoSlim® has been studied for enhancing metabolic functions whereas many lab studies have demonstrated the potential efficacy of InnoSlim® for the blood sugar and blood lipids regulation. There has been no relevant human study on InnoSlim® on blood sugar and blood lipids regulation. There have reported that 2018 estimating the total costs of diagnosed diabetes have risen to $327 billion in 2017 from $245 billion in 2012. Although pharmacological methods have been developed to treat diabetes, these treatments can be costly and are not without potential adverse effects. The development of dietary agents for the prevention of diabetes could represent a cost-effective and safe means to deal with this growing public health crisis.

In this study, the investigators are investigating the effects of InnoSlim® on blood sugar and blood lipids regulation in humans. The testing sample is orally administrated to participants with pre-diabetes and hyperlipidemia humans, the efficacy parameters of blood sugar, lipid profile and other parameters, as well as adverse effects to the healthy individual, are screened during the trial, the significant difference is shown and no adverse effect reported.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

Conditions

Hyperlipidemia

InnoSlim®DIETARY_SUPPLEMENT

Subjects take 2 capsules before breakfast and 3 capsules before dinner of similar appearance per day for 6 weeks of a stage.

PlaceboDIETARY_SUPPLEMENT

Subjects take 2 starch capsules before breakfast and 3 starch capsules before dinner of similar appearance per day for 6 weeks of a stage.

Eligibility

Sex: ALLMin age: 20 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Participants age 20 years and above. * Participant has provided written and dated informed consent to participate in the study. * Participant is willing and able to comply with the study. * Participants blood sugar (100≤ fasting blood glucose ≤ 125 mg/dL and 5.7%≤HbA1c ≤ 6.4% ) and Total cholesterol ≥200 mg/dL Exclusion Criteria: * Participant is participating in another clinical trial thirty days prior to enrollment. * Participant has a significant history or current presence of treated or untreated heart disease, kidney disease, liver disease, muscle disease, bone disease, or a history of surgery. * Participant has any medical condition or uses any medication, nutritional product, dietary supplement or program which might interfere with the conduct of the study or place the subject at risk. * Participants lost to follow-up, non-compliance, concomitant medication.

Outcomes

Primary Outcomes

The changes of fasting blood glucose of the subjects

A randomized-double blind, and crossover trial values change of fasting blood glucose between before to after0, 3, 6, 10, 13 \& 16weeks

Time frame: 16 weeks

Secondary Outcomes

he changes of cholesterol of the subjects

A randomized-double blind, and crossover trial values change of blood lipid between before to after0, 3, 6, 10, 13 \& 16weeks

Time frame: 16 weeks

he changes of triglyceride of the subjects

A randomized-double blind, and crossover trial values change of blood lipid between before to after0, 3, 6, 10, 13 \& 16weeks

Time frame: 16 weeks

Effect of InnoSlim® on Blood Sugar and Blood Lipids Regulation in Humans

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes